S-1 combination regimen effective for NSCLC

Researchers suggest that combined therapy with the fluoropyrimidine S-1, carboplatin, and bevacizumab followed by maintenance therapy with S-1 and bevacizumab should be first-line treatment for patients with advanced non-squamous non-small-cell lung cancer.

via Med Wire News